These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 19657699

  • 1. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
    Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, Miki C, Kusunoki M.
    Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
    [Abstract] [Full Text] [Related]

  • 2. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
    Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Koike Y, Fujikawa H, Inoue Y, Miki C, Kusunoki M.
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
    [Abstract] [Full Text] [Related]

  • 3. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
    Yasuda H, Tanaka K, Saigusa S, Toiyama Y, Koike Y, Okugawa Y, Yokoe T, Kawamoto A, Inoue Y, Miki C, Kusunoki M.
    Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
    Sprenger T, Conradi LC, Beissbarth T, Ermert H, Homayounfar K, Middel P, Rüschoff J, Wolff HA, Schüler P, Ghadimi BM, Rödel C, Becker H, Rödel F, Liersch T.
    Cancer; 2013 Jan 01; 119(1):26-35. PubMed ID: 22736392
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
    Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J.
    Histopathology; 2009 Sep 01; 55(3):284-93. PubMed ID: 19723143
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy.
    Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Fujikawa H, Matsushita K, Uchida K, Inoue Y, Kusunoki M.
    Surg Today; 2012 May 01; 42(5):460-9. PubMed ID: 22072148
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study.
    Hongo K, Kazama S, Tsuno NH, Ishihara S, Sunami E, Kitayama J, Watanabe T.
    World J Surg Oncol; 2015 Jan 27; 13():7. PubMed ID: 25622595
    [Abstract] [Full Text] [Related]

  • 14. Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy.
    Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Kawamura M, Okugawa Y, Okigami M, Hiro J, Uchida K, Mohri Y, Kusunoki M.
    J Cancer Res Clin Oncol; 2013 Jan 27; 139(1):131-8. PubMed ID: 22986809
    [Abstract] [Full Text] [Related]

  • 15. Identification of Predictors of Recurrence in Patients with Lower Rectal Cancer Undergoing Neoadjuvant Chemotherapy: A Direct Comparison of Short-Course and Long-Course Chemoradiotherapy.
    Yamamoto A, Toiyama Y, Okugawa Y, Saigusa S, Ide S, Fujikawa H, Hiro J, Yasuda H, Yoshiyama S, Ohi M, Araki T, Kusunoki M.
    Oncology; 2019 Jan 27; 96(2):70-78. PubMed ID: 30227430
    [Abstract] [Full Text] [Related]

  • 16. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.
    Akiyoshi T, Ueno M, Matsueda K, Konishi T, Fujimoto Y, Nagayama S, Fukunaga Y, Unno T, Kano A, Kuroyanagi H, Oya M, Yamaguchi T, Watanabe T, Muto T.
    Ann Surg Oncol; 2014 Jan 27; 21(1):189-96. PubMed ID: 23963871
    [Abstract] [Full Text] [Related]

  • 17. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.
    Cortes-Dericks L, Galetta D, Spaggiari L, Schmid RA, Karoubi G.
    Eur J Cardiothorac Surg; 2012 Jun 27; 41(6):e173-81. PubMed ID: 22529186
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
    Kim CW, Yu CS, Yang SS, Kim KH, Yoon YS, Yoon SN, Lim SB, Kim JC.
    Ann Surg Oncol; 2011 Nov 27; 18(12):3271-7. PubMed ID: 21537868
    [Abstract] [Full Text] [Related]

  • 19. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H, Zeng F, Xu L, Liu X, Huang Y.
    Mol Med Rep; 2013 Nov 27; 8(5):1511-8. PubMed ID: 24008862
    [Abstract] [Full Text] [Related]

  • 20. Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.
    Sadahiro S, Suzuki T, Tanaka A, Okada K, Saito G, Miyakita H, Ogimi T, Nagase H.
    Cancer Chemother Pharmacol; 2017 Jun 27; 79(6):1077-1085. PubMed ID: 28417167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.